Abstract:
Vaccination guidelines for recipients of blood and marrow transplantation ( consults" which often began with: "Do you mind if I just ask you a vaccine question?" We share our answers to these FAQs as a concise practical and pragmatic review; the intent is to facilitate good clinical practice in patients of all ages. We also provide an auto-filled Excel immunization schedule table for our recommended BMT approach to early or standard vaccination (hotlink to electronic Supplement 2).
Top 20 Frequently Asked Questions (FAQs)

General:
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FAQ1: When should vaccinations begin for the typical BMT recipient?
Consensus guidelines recommend initiating vaccinations at 3-6 months after BMT noting that this lacks prospective validation.
1-5 Given the variable tempo of IR (see sFAQ1), particularly in patients transplanted for primary immunodeficiency diseases (see FAQ4), the negative impact of moderate to severe GVHD on IR, and potential use of in vivo T or B cell depleting therapies, we prefer to select candidates for "early vaccination" at 6 months based on favorable responses to a 6-question algorithm (Figure 2 ). Any unfavorable response triggers vaccine deferral (except for flu shots) until at least 1 year posttransplant. Our approach takes into consideration that vaccine efficacy depends on at least partial reconstitution of adaptive immunity.
FAQ2: Should BMT recipients be vaccinated if they already have protective titers?
Yes. Antibody titers to vaccine-preventable diseases decline after autologous (see sFAQ2) or allogeneic BMT despite the fact that most BMT recipients were vaccinated earlier in life. 6 Clinical relevance of declining titers is not immediately apparent because the number of vaccine-preventable diseases reported among BMT recipients is limited.
Nonetheless, diseases potentially prevented by vaccines still pose increased risks for BMT recipients until immunity is fully restored. Therefore, with exception of viruses exhibiting latency outside the hematopoietic system (e.g. varicella), BMT recipients should be re-vaccinated against pathogens contained in childhood primary immunization schedules.
FAQ3: Is vaccination appropriate for patients receiving immunoglobulin therapy?
For (ii) Detectable serum IgA (>6 mg/dL) suggesting ability to "Ig class switch".
(iii) Donor B cells >200/μL as determined by percent donor B cell chimerism multiplied by the total absolute B cell count. This threshold is arbitrarily set 1-log higher than for non-primary immunodeficiencies diseases.
(iv) Donor CD4 cells 200/μL as determined by percent donor CD4 chimerism multiplied by the total absolute CD4 T cell count. given LAIV, a 7-day furlough is advised. 10 Live attenuated oral polio vaccine that is still available in some non-U.S. countries should not be used and if inadvertently given to a household contact, a 4-6 week furlough is advised.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Diptheria/Tetanus/Acellular-Pertussis (DTaP/Tdap) Tetanus toxoid revaccination is relevant given the ubiquitous environmental exposure to tetanus and the seriousness of disease due to tetanus toxin. While diphtheria is essentially eradicated, ongoing vaccination is critical for herd immunity and pertussis outbreaks have been prevalent in states where herd immunity has waned. It is important to remember that in the pre-vaccination era (1920s-1940s), annual U.S. death rates for pertussis were 5,000-10,000.
FAQ7: Should I administer DTaP or Tdap?
Consensus guidelines favor 3 doses of DTaP regardless of age, although this policy is inconsistent with U.S. recommendations because DTaP is only licensed for <7 years of age. Without data to support DTaP being safe and more effective than Tdap for BMT recipients aged ≥ 7 years, the Consensus approach needs to be weighed by individual centers. The argument to offer DTaP and not Tdap for older BMT recipients is that 10-fold higher doses of diphtheria and pertussis toxoids in DTaP should elicit better antibody responses. This argument aligns with the fact that early vaccination could include patients who remain on IST (FAQs 1, 4). For reference, the strength of the recommendation for 3 doses of pediatric DTaP vaccine in <7 year-olds is rated by IDSA as "strong" with only "low" quality supporting evidence. In contrast, the same 3 dose DTaP series in ≥ 7 year-olds (ie. non-FDA-approved use) is rated with a "weak" recommendation and "very low" quality of evidence. Finally, the FDA/ACIP-approved 3-dose series for ≥ 7 year-olds (Tdap/Td/Td) also carries a "weak" recommendation with "low" rather than "very low" quality evidence. It is unclear whether DTaP side effects are related to higher doses of "D" or "aP" antigens. One study in healthy adults demonstrated that the aP vaccine was safe and relatively non-reactogenic even at high doses.
11 Currently, compliance with FDA licensure limits U.S. practice to the potentially inferior Tdap vaccine. If we restrict the use of a 3 shot DTaP series to <7 year olds, the testable question remains whether 3 doses of Tdap would be better than Tdap/Td/Td for those over 7 years of age.
Hemophilus influenzae type B (Hib)
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Hepatitis A (HAV) and Hepatitis B (HBV)
Hepatitis A infection can be serious and prolonged, particularly in older children, teens and adults. A two shot series is advised to provide durable protective immunity.
Routine U.S. childhood HBV vaccination after 1990 contributed to a >80% decline but incomplete eradication of new acute hepatitis B cases. Thirty to 50% of infected persons aged 5 years and older have initial signs and symptoms for up to 6 months. Fatality rates for CDC-reported acute cases are 0.5%-1% and disease is more severe among older adults. While 95% of adults recover and clear the infection, 90% of infants (and up to 50% aged 1-5 years) will remain chronically infected. Fatality rates for chronic HBV induced cirrhosis or hepatocellular carcinoma are 25% if infection is acquired during childhood and 15% if infected at older ages. There is no treatment for acute infection; chronic infection involves chronic antiviral therapy and regular monitoring to screen for liver damage and cancer. Not surprisingly, broad ACIP HBV vaccine recommendations include immunocompromised individuals.
FAQ8: How should HAV and HBV vaccines be dosed in BMT recipients?
HAV vaccination does not differ for immunocompetent and immunocompromised individuals. However, because HBV vaccine antigen doses need to be higher for adult hemodialysis patients to induce protective antibody, the CDC suggests that higher doses or additional doses of HBV vaccine might also be necessary for other immune compromised individuals. We interpret this to include BMT recipients at least until they reach the milestone of being 6 months off all IST. The nuances of age-related HAV and HBV vaccine dosing and use of combination vaccines are detailed in Tables 1 and 2 (see also sFAQs 16-22).
Human Papillomavirus
FAQ9: Why is vaccination against HPV advised for young BMT recipients?
HPV infection is caused by the most common sexually transmitted virus in the U.S., with >50% of sexually active individuals infected (mostly asymptomatically) during their lifetimes. HPV is responsible for cervical, vaginal and vulvar cancer in women and is the second leading cause of cancer deaths in women worldwide. HPV is also responsible for genital warts and anal cancers in both genders; genital warts can be serious in immunocompromised individuals.
FAQ10: Which HPV vaccine should be administered after BMT?
Among three currently available HPV vaccines (4vHPV, 2vHPV, 9vHPV), 9-valent HPV has the potential to prevent approximately 90% of cervical, vulvar, vaginal and anal cancers. It protects against cervical cancer and genital warts. 2vHPV protects against serotypes that are responsible for ~70% of cervical cancer, but does not contain HPV types 6 and 11 that are responsible for over 90% of genital warts. ACIP currently advises vaccination with either 4vHPV or 9vHPV in immunocompromised persons age 9 through 26 years (see sFAQ23).
12 Although two doses may be sufficient for 4vHPV vaccine in healthy individuals, 13 absence of data in BMT leads us to advise three doses be recommended.
Influenza vaccine
Although annual influenza vaccination is a "universal" ACIP recommendation for all individuals age Vaccination strategies first consider that meningococcal disease is most frequent among: infants, pre-teen/adolescents who are the primary focus group for vaccination and, over 65 year-olds among whom 60% of cases are attributable to serogroup Y.
Beyond these age groups, other individuals are considered to be at higher risk.
FAQ14: Who should receive which meningococcal vaccine?
We advise that all BMT recipients over 9 months of age and ACIP recently advised that a multicomponent Men-B antigen vaccine be given routinely to high-risk individuals ≥ 10 years old, in addition to MCV4, and may be offered on an individual basis to any adolescent or young adult at a preferred age of 16-18 years. This came about due to the availability of safe and immunogenic vaccines and increasing meningococcal B outbreaks. 17 We would consider off-label use for >25 year-olds with functional or anatomic asplenia (e.g. chronic GVHD) or those with work-place risks (see Table 3 and sFAQ29).
Measles, Mumps, Rubella, Varicella (MMR/MMVR)
Measles is a highly contagious airborne respiratory disease that caused ~2.6 million deaths globally per year before widespread vaccination. 18 Measles complications include high fever, rash, blindness, life-threatening diarrhea, encephalitis or pneumonia. Mumps complications can be more serious in adults than children and include viral meningitis, For personal use only. on October 24, 2017. by guest www.bloodjournal.org From orchitis, oophoritis, mastitis, and deafness. Rubella complications include polyarthralgia, encephalitis, thrombocytopenia, and potentially devastating congenital rubella syndrome.
FAQ15: When and how should MMR vaccination be given after BMT?
It is considered safe to give live attenuated MMR when recipients are 
FAQ16: How do the two available pneumococcal vaccines types differ?
PPSV23 (Pneumovax) is the original polysaccharide capsular vaccine offering protection against 23 serotypes of pneumococcus known to cause disease in humans (Table 4) .
Twelve of these serotypes plus the 6A serotype not contained in PPSV23 account for >50% of IPD in children and form the basis of the more effective protein conjugated PCV13 vaccine (Prevnar) that was developed originally for young children. Among immunocompromised children, another 25% of IPD cases involved additional serotypes included in PPSV23. Post-2000 herd immunity that followed introduction of the earlier PCV7 vaccine in children also led to a reduction in IPD among older children and adults.
PCV13, a T cell dependent vaccine, is more immunogenic than PPSV23 because it triggers memory response that leads to more durable protection than PPSV23 which confers only 3-5 years of protection. It is worth remembering that PPSV23 is particularly ineffective in young children age <2 years.
3
FAQ17: What pneumococcal vaccination schedule is ideal after BMT?
Unless a patient is severely immunocompromised, we begin PCV13 vaccination at ≥ 6 months, with 3 doses, 1-2 months apart (Figure 2) . 20, 21 One dose of PPSV23 is then given 6-12 months (minimum 8 weeks) after the last PCV13. The goal is broader coverage to all 23 pneumococcal serotypes (see sFAQs 31, 32). Starting at month 3 versus 9 with PCV7 was equally effective but pneumococcal titers declined faster for the month 3 cohort; therefore a fourth dose is advised. 20 Priming for PPSV23 vaccination was inferior if vaccination began at month 3. PCV13 responses were inferior for older recipients, donors other than matched siblings, and IgG <400 mg/dL. 21 Cord blood or haplorelated grafts were not addressed and extensive chronic GVHD occurred infrequently in both studies. Fig 2) ? Timing of varicella vaccination can be remembered as for MMR by the "2-1-8" rule (see FAQ15). A second dose of varicella vaccine is needed >1 month after the first.
FAQ18: Are there exceptions or modifications to the pneumococcal vaccination schedule in FAQ17 (
Yes
Addressing Vaccine Hesitant Patients/Parents
FAQ20: How to address vaccine hesitancy/resistance in patients/parents?
There is no single best way to tackle this problem. Prospective pediatric studies led Opel et al to advise being presumptive (e.g. "It is time to do shots") rather than being participatory (e.g. "What do you want to do about shots?"). 22 Participatory approaches resulted in more parents verbalizing initial resistance to one or more vaccines, even after controlling for vaccine-hesitancy status. In contrast, when the provider just states which vaccines a child is due to receive, most parents have no issues with vaccines. It's fine to presume that the parent you are seeing will be one of the majority. Middle ground might include being presumptive while offering parents an opportunity to express their own preference, for example, "Today, Johnny gets his DTaP, Prevnar and Hib. Sound OK?".
If a participatory approach is preferred, commit to pursuing any refusals, concerns or questions knowing that about half of the initially vaccine resistant parents and a quarter of vaccine-hesitant parents will change their mind (see sFAQ4-6).
While there is no evidence for vaccination with anything but the recommended schedule, if we have thoroughly explored the reasons for delaying or refusing vaccination and have been unable to convince them otherwise, we would argue that alternative schedules that at least partially immunize the child (patient) are probably better than the alternative of requesting that the parent (patient) seek care elsewhere. Footnote: B cell numbers are low in the first 1-2 months and normalize during months 3-12. B cell recovery is delayed by at least 6 months after anti-B cell antibody therapy. Antigen specific responses are impaired also because of limited capacity to undergo somatic mutation and isotype switch during the first year. Normalization of IgA levels can be indicative of isotype switching and is unaffected by IVIG replacement therapy. CD4 counts are generally less than 200/μL during the 1 st 3 months. Thereafter, recovery is highly variable; generally >200/μL by 6-9 months if age <18 years and no chronic GVHD. Adults with chronic GVHD may take more than 2 years. For these reasons, some institutions defer vaccination until the peripheral CD4 count is >200/μL and the CD19 (B cell) count >20 /μL. Most circulating T cells at year 1 (especially in adults) are memory/effector T cells derived from infused T cells. These cells can respond to antigens encountered by the donor pre-HCT. Naïve T cells that respond to neoantigens are generated only at 6-12 months (earlier in young children, later in old adults). Only limited data exist for the settings of unrelated cord blood and haploidentical-HCT or after reduced intensity regimens and so, for the sake of simplicity, the algorithm does not make further adjustments on these bases. ** Which agents are sufficiently immunosuppressive to prevent effective vaccination has not been studied. Other than the seasonal flu shot, most vaccinations are avoided when BMT recipients are receiving azacytidine, lenalidomide or rituximab. We tend to still administer vaccines if patients have little or no chronic GVHD and are on kinase inhibitors (e.g. imatinb or sorafenib).
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